|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 270.10 USD | -3.51% |
|
-6.19% | -11.10% |
| 02/06 | BeOne Medicines Solid Tumor Data Boost Confidence in Long-term Growth, RBC Says | MT |
| 02/06 | RBC Raises Price Target on BeOne Medicines to $436 From $425, Keeps Outperform Rating | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 411.91 | +52.5% | 28 | ||||||
| 663.52 | +36.64% | 23 | ||||||
| 186.33 | +24.86% | 21 | ||||||
| 227.1 | +21.52% | 20 | ||||||
| 2,52,207.11 | +47.15% | 24 | ||||||
| 70.89 | +9.19% | 14 | ||||||
| 442.83 | -3.46% | 12 | ||||||
| 100.92 | +35.5% | 25 | ||||||
| 153.25 | +0.29% | 16 | ||||||
| 66.53 | +43.3% | 15 | ||||||
| 212.27 | +17.05% | 15 | ||||||
| 61.42 | +18.13% | 12 | ||||||
| 114.77 | +30.64% | 7 | ||||||
| 43.82 | +19.46% | 14 | ||||||
| 627.59 | +137.05% | 17 | ||||||
| 45.44 | +4.74% | 16 | ||||||
| 118.35 | +30.2% | 17 | ||||||
| 45.76 | +47.11% | 17 | ||||||
| Average | 14,211.1 | +31.77% | 17 | ||||||
| Weighted average by Cap. | 22,325.27 | +31.76% | 20 |
- Stock Market
- Equities
- ONC Stock
- Sector BeOne Medicines AG
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition